Comparing two imaging techniques for ovarian cancer diagnosis
A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer
This study is testing if a new imaging technique can better diagnose and stage ovarian cancer compared to the standard method for patients who have already been diagnosed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 20 Years to 65 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Xiamen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Xiamen, Fujian) |
| Trial ID | NCT05824247 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 68Ga-FAPI-PET-CT compared to traditional FDG-PET-CT in diagnosing and staging ovarian cancer. It aims to determine whether FAPI-PET-CT can serve as a better evaluation tool for surgical resection and predicting chemotherapy response. The study involves patients with confirmed primary epithelial ovarian cancer who will undergo imaging evaluations. By focusing on cancer-associated fibroblasts, the study seeks to improve diagnostic accuracy and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients with primary epithelial ovarian cancer confirmed by clinical evaluation or biopsy.
Not a fit: Patients with acute inflammation, severe complications, or contraindications to PET-CT will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnosis and better treatment planning for patients with ovarian cancer.
How similar studies have performed: Previous studies have shown that PET-CT imaging can significantly improve the staging and management of ovarian cancer, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with primary epithelial ovarian cancer confirmed by clinical consideration or puncture 2. PET-CT was chose as the initial imaging evaluation tool. Exclusion Criteria: 1. Patients with acute inflammation 2. Lacking of clinical data 3. Severe complications and PET-CT contraindications
Where this trial is running
Xiamen, Fujian
- First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China (Recruiting)
Study contacts
- Study coordinator: JianFa Lan, Doctor
- Email: 407136123@qq.com
- Phone: 18810535017
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.